CUE

Cue Biopharma, Inc. (CUE) | Rumor.io

Cue Biopharma

CUE

Attention (50-day avg)0%

Attention rank (50-day avg)#1,200

Bullish sentiment (50-day avg)63%

Price to earnings ratio-3.27

Market capitalization199.4M

Earnings per share-29.5

Dividend yield (TTM)—

Revenue (annual)27.5M

Net income (annual)-26.6M

Social

What share of all stock conversation is about CUE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0.01% +0.01	0% +0	0% +0

Sep 21

Cue Biopharma's Phase 2 study for chronic hives shows promising results, with 145-patient study yielding positive data.
The company's licensed asset, CUE-221, is now the focus of attention, with its potential to change the story for a small biotech being discussed.
Despite the positive data, Cue Biopharma's stock price has taken a hit, with a 27.4% intraday drop, trading near $26.90 after closing at $37.05.

Generated by AI

Sentiment

Of the messages about CUE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	45.98% -54.02	57.27% -31.62	84.02% -2.79
Bearish	—	54.02% +54.02	42.73% +31.62	15.98% +2.79

Bullish· Sep 21

The company has a promising clinical data and a huge potential market, with the current valuation not reflecting the potential.
The drug has a whole new mechanism from omalizamab and durability data from Phase 2B/3 trials, which could make it the first line biological treatment.
The stock has strong science and well-differentiated data against Xolair, with a potential target price of $33 or higher.

Bearish· May 1

$CUE's recent price surge is unlikely to hold, with one user predicting a retrace back to $17.
The warrants issued at $11 are expected to prop up the price until Monday, after which the asset may plummet due to the PIPE finalizing.
A history of rapid price spikes followed by sharp declines suggests that $CUE's current price may be a short-term opportunity that will soon fade.

Generated by AI

Topics

Of the messages about CUE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	41.62%	59.41%	57.62%
Analysts	—	14.45%	12.55%	11.23%
Controversies	—	22.54%	14.39%	3.3%
Macro	—	20.23%	12.92%	7.97%
Technical Analysis	—	1.16%	0.74%	17.8%
Earnings	—	0%	0%	2.07%

Announcements· May 1

Cue Biopharma, Inc. ($CUE) announced a $30 million private placement to fund its pipeline, including the autoimmune program CUE-401.
The company also entered into an exclusive global license agreement with Ascendant Health Sciences to develop, manufacture, and commercialize Ascendant-221, an anti-IgE antibody.
Cue Biopharma appointed a new CEO as part of a trifecta of news that also included the $30 million private placement and an exclusive license agreement.

Technical Analysis· May 1

$CUE is approaching a potential break of $30, which could bring in strong buying and selling volume.
The stock's technical structure presents a high-risk setup, with a potential "bull trap" or failed breakout, and the RSI has cooled, suggesting that the momentum phase is exhausted.
$CUE is showing signs of a potential breakout, with a possible run up to at least $33, and a strong volume breakout, confirming the momentum.

Generated by AI

Community

Of the messages about CUE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	28.09%	23.71%	18.45%
Newcomers	0%	71.91%	76.29%	81.55%

Regulars· Sep 21

Cue Biopharma's shares were down 27.4% intraday, trading near $26.90, despite a pre-market surge sparked by positive Phase 2 data.
Some regular investors are optimistic about the stock's potential, with one user predicting a price of $100, and another calling the current price a "great buying opportunity".
The recent Phase 2 data and the company's performance have caused some investors to reassess their positions, with one user breaking even on their investment and another selling a portion of their shares at $55.50.

Newcomers· Sep 21

The Phase 2 readout for CUE-221 has shown positive results in treating chronic hives, beating placebo and demonstrating longer-lasting relief than Xolair after dosing stopped.
The data is well-differentiated against Xolair, particularly at weeks 22 and beyond, suggesting that CUE-221 could become a first-line biological treatment.
The current valuation of CUE does not reflect its potential, with strong science and promising clinical data supporting a huge potential market for the company's treatment.

Generated by AI

Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate

2d agoYahoo Finance

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

4d agoYahoo Finance

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CUE) 2026-09-24

2026-09-24. The following slide deck was published by Cue Biopharma, Inc.

5d agoSeeking Alpha

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

8d agoSeeking Alpha

Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset

8d agoSeeking Alpha

What's Going on With Cue Biopharma Stock on Monday? - Cue Biopharma (NASDAQ:CUE)

Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.

8d agoBenzinga

Also Discussed

Investors talking about CUE also mention

#	Name	Attention
1	PRVB - Provention Bio, Inc.	——
2	Immunome, Inc.IMNM	0%-0.01
3	OneConstruction Group Ltd.ONEG	0%0
4	Atomera IncATOM	0%+0
5	Nuvation Bio Inc.NUVB	0%0
6	Gain Therapeutics, Inc.GANX	0.04%+0.02
7	INmune Bio Inc.INMB	0%0
8	TFFP - TFF Pharmaceuticals, Inc.	——
9	Coya Therapeutics, Inc.COYA	0%new
10	Pulse Biosciences IncPLSE	0%+0

Cue Biopharma, Inc.

Healthcare
Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression. The company’s lead asset, CUE-221, is an anti-IgE antibody being advanced for allergic diseases, while CUE-401 is a bifunctional IL-2 and TGF-β program designed to support Treg-mediated tolerance in autoimmune conditions. Cue Biopharma’s Immuno-STAT platform underpins its product development approach, enabling targeted immune modulation across immunological disorders. Based in Boston, Massachusetts, Cue Biopharma participates in the biotechnology sector through a pipeline aimed at addressing unmet medical needs in allergy, inflammation, and autoimmunity.

Website

Location

40 Guest Street

Boston, MA, 02135

United States

Social

What share of all stock conversation is about CUE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0.01% +0.01	0% +0	0% +0

Sep 21

Cue Biopharma's Phase 2 study for chronic hives shows promising results, with 145-patient study yielding positive data.
The company's licensed asset, CUE-221, is now the focus of attention, with its potential to change the story for a small biotech being discussed.
Despite the positive data, Cue Biopharma's stock price has taken a hit, with a 27.4% intraday drop, trading near $26.90 after closing at $37.05.

Generated by AI

Sentiment

Of the messages about CUE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	45.98% -54.02	57.27% -31.62	84.02% -2.79
Bearish	—	54.02% +54.02	42.73% +31.62	15.98% +2.79

Bullish· Sep 21

The company has a promising clinical data and a huge potential market, with the current valuation not reflecting the potential.
The drug has a whole new mechanism from omalizamab and durability data from Phase 2B/3 trials, which could make it the first line biological treatment.
The stock has strong science and well-differentiated data against Xolair, with a potential target price of $33 or higher.

Bearish· May 1

$CUE's recent price surge is unlikely to hold, with one user predicting a retrace back to $17.
The warrants issued at $11 are expected to prop up the price until Monday, after which the asset may plummet due to the PIPE finalizing.
A history of rapid price spikes followed by sharp declines suggests that $CUE's current price may be a short-term opportunity that will soon fade.

Generated by AI

Topics

Of the messages about CUE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	41.62%	59.41%	57.62%
Analysts	—	14.45%	12.55%	11.23%
Controversies	—	22.54%	14.39%	3.3%
Macro	—	20.23%	12.92%	7.97%
Technical Analysis	—	1.16%	0.74%	17.8%
Earnings	—	0%	0%	2.07%

Announcements· May 1

Cue Biopharma, Inc. ($CUE) announced a $30 million private placement to fund its pipeline, including the autoimmune program CUE-401.
The company also entered into an exclusive global license agreement with Ascendant Health Sciences to develop, manufacture, and commercialize Ascendant-221, an anti-IgE antibody.
Cue Biopharma appointed a new CEO as part of a trifecta of news that also included the $30 million private placement and an exclusive license agreement.

Technical Analysis· May 1

$CUE is approaching a potential break of $30, which could bring in strong buying and selling volume.
The stock's technical structure presents a high-risk setup, with a potential "bull trap" or failed breakout, and the RSI has cooled, suggesting that the momentum phase is exhausted.
$CUE is showing signs of a potential breakout, with a possible run up to at least $33, and a strong volume breakout, confirming the momentum.

Generated by AI

Community

Of the messages about CUE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	28.09%	23.71%	18.45%
Newcomers	0%	71.91%	76.29%	81.55%

Regulars· Sep 21

Cue Biopharma's shares were down 27.4% intraday, trading near $26.90, despite a pre-market surge sparked by positive Phase 2 data.
Some regular investors are optimistic about the stock's potential, with one user predicting a price of $100, and another calling the current price a "great buying opportunity".
The recent Phase 2 data and the company's performance have caused some investors to reassess their positions, with one user breaking even on their investment and another selling a portion of their shares at $55.50.

Newcomers· Sep 21

The Phase 2 readout for CUE-221 has shown positive results in treating chronic hives, beating placebo and demonstrating longer-lasting relief than Xolair after dosing stopped.
The data is well-differentiated against Xolair, particularly at weeks 22 and beyond, suggesting that CUE-221 could become a first-line biological treatment.
The current valuation of CUE does not reflect its potential, with strong science and promising clinical data supporting a huge potential market for the company's treatment.

Generated by AI

Cue Biopharma

Social

Sep 21

Bullish· Sep 21

Bearish· May 1

Announcements· May 1

Technical Analysis· May 1

Regulars· Sep 21

Newcomers· Sep 21

Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CUE) 2026-09-24

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset

What's Going on With Cue Biopharma Stock on Monday? - Cue Biopharma (NASDAQ:CUE)

Also Discussed

Cue Biopharma, Inc.

Company Information

Location

Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CUE) 2026-09-24

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset

What's Going on With Cue Biopharma Stock on Monday? - Cue Biopharma (NASDAQ:CUE)

Also Discussed

Social

Sep 21

Bullish· Sep 21

Bearish· May 1

Announcements· May 1

Technical Analysis· May 1

Regulars· Sep 21

Newcomers· Sep 21